King & Wood Mallesons (KWM), advised TVM Capital Life Science (TVM Capital), on the first closing of its China BioPharma Capital Fund (China BioPharma), raising more than $50 million in commitments.

TVM Capital Life Science is a group of independent investment advisors and fund managers for Venture Capital funds investing in innovative biotech, pharmaceutical, and medtech companies in Europe, Canada the USA and Asia. The teams are based in Munich, Montréal and Asia.

China BioPharma is a venture capital fund; one of its investors is Chongqing Lummy Pharmaceutical Co., a Chinese pharmaceutical company. China BioPharma focuses on investments in life science innovation in Western companies and has the objective to obtain licenses for development and commercialization in China.

With its exceptional expertise in fund structuring and its unrivalled understanding of fundraising requirements, KWM has unparalleled industry insight. The International Funds Team structures the most funds worldwide and advises on all legal and economic aspects of fund structuring.

KWM China office, Hong Kong office and Germany office made a cross-regional cooperation in this project. Co-Chief Executive of KWM Hong Kong office, Zhang Yi and partner Alan Du from China office and partner Sonya Pauls and Christian Schatz from Germany office provided professional and attentive legal service to the client.